United States Biotechnology & Medical Research

Galera Therapeutics Inc (GRTX)

Track

Track

The most recent insider trading activity occurred on November 20, 2025, involving a sale of 70,000 shares by CEO Mel Sorensen. Prior to this, Nancy Chang acquired a significant stake in December 2024. These transactions represent the latest recorded movements within the company's equity structure.
Ticker: GRTX Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Galera Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.6
Sorensen Mel President and CEO Executive Director
Transaction date
Sale
Price
235.78
Quantity 3,343 +1.0%
Value US$464,447
2.6
Sorensen Mel Officer Officer
Transaction date
Proposed sale
Price
289.73
Quantity 816
Value US$4,580,759
CHANG NANCY T Non-Executive Director Large shareholder
Transaction date
Purchase
Price
358.69
Quantity 63,773 +36.8%
Value US$4,740,093
2.6
Sorensen Mel President and CEO Executive Director
Transaction date
Sale
Price
0.07
Quantity 67,015 -20.2%
Value US$4,825
2.6
Sorensen Mel Officer; Director Executive Director
Transaction date
Proposed sale
Price
0.07
Quantity 67,015
Value US$4,825
2.7
Schneid Yair Large shareholder
Transaction date
Purchase
Price
0.17
Quantity 150,000 +1.9%
Value US$25,650
2.7
Schneid Yair Large shareholder
Transaction date
Purchase
Price
0.17
Quantity 150,000 +1.9%
Value US$25,935
2.7
Schneid Yair Large shareholder
Transaction date
Purchase
Price
0.17
Quantity 25,000 +0.3%
Value US$4,250
2.7
Schneid Yair Large shareholder
Transaction date
Purchase
Price
0.20
Quantity 25,000 +0.3%
Value US$5,025
2.7
Schneid Yair Large shareholder
Transaction date
Purchase
Price
0.18
Quantity 97,402 +1.3%
Value US$17,922
2.7
Schneid Yair Large shareholder
Transaction date
Purchase
Price
0.18
Quantity 335,000 +4.6%
Value US$60,635
2.7
Schneid Yair Large shareholder
Transaction date
Purchase
Price
0.18
Quantity 150,000 +2.1%
Value US$27,000
3.2
Bachleda Mark Chief Commercial Officer Officer
Transaction date
Purchase
Price
2.25
Quantity 11,000 +inf%
Value US$24,717
2.2
Degnan Chris Chief Financial Officer Officer
Transaction date
Purchase
Price
1.96
Quantity 10,000 +inf%
Value US$19,593
2.6
Sorensen Mel President and CEO Executive Director
Transaction date
Purchase
Price
1.68
Quantity 100,000 +43.1%
Value US$168,120
2.7
West Linda Non-Executive Director
Transaction date
Purchase
Price
2.74
Quantity 20,000 +50.0%
Value US$54,804
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
8.47
Quantity 47,756 -100.0%
Value US$404,498
2.7
West Linda Non-Executive Director
Transaction date
Purchase
Price
9.13
Quantity 10,000 +33.3%
Value US$91,300
2.7
West Linda Non-Executive Director
Transaction date
Purchase
Price
8.65
Quantity 10,000 +50.0%
Value US$86,511
1.8
Alleva Lawrence M Non-Executive Director
Transaction date
Purchase
Price
8.59
Quantity 4,045 +inf%
Value US$34,741
2.7
West Linda Non-Executive Director
Transaction date
Purchase
Price
8.64
Quantity 10,000 +100.0%
Value US$86,381
2.7
West Linda Non-Executive Director
Transaction date
Purchase
Price
8.64
Quantity 10,000 +inf%
Value US$86,410
2.3
Novo Holdings A/S Large shareholder
Transaction date
Sale
Price
10.58
Quantity 500,000 -16.9%
Value US$5,290,000
1.8
Alleva Lawrence M Non-Executive Director
Transaction date
Purchase
Price
10.22
Quantity 2,325 +58.1%
Value US$23,771
1.1
Sussman Joel F. Chief Accounting Officer Officer
Transaction date
Sale
Price
10.32
Quantity 10,000 -100.0%
Value US$103,197
1.1
Sussman Joel F. Chief Accounting Officer Officer
Transaction date
Sale
Price
10.06
Quantity 10,000 -100.0%
Value US$100,627
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
15.00
Quantity 2,244 -100.0%
Value US$33,660
2.3
Novo Holdings A/S Large shareholder
Transaction date
Sale
Price
11.00
Quantity 450,000 -13.2%
Value US$4,950,000
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 10,536 -100.0%
Value US$126,432
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 100 -100.0%
Value US$1,200
2.7
Novartis Bioventures Ltd Former 10% Owner
Transaction date
Sale
Price
8.25
Quantity 1,001,312 -28.9%
Value US$8,260,824
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 692 -100.0%
Value US$8,304
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 1,174 -100.0%
Value US$14,088
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 969 -100.0%
Value US$11,628
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 671 -100.0%
Value US$8,052
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 185 -100.0%
Value US$2,220
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 5,102 -100.0%
Value US$61,224
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 2,059 -100.0%
Value US$24,709
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 1,489 -100.0%
Value US$17,868
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.16
Quantity 3,064 -100.0%
Value US$37,258
Alleva Lawrence M Non-Executive Director
Transaction date
Purchase
Price
9.78
Quantity 4,000 +inf%
Value US$39,139
1.5
Clarus IV-A, L.P. Large shareholder
Transaction date
Purchase
Price
12.00
Quantity 19,423 +17.5%
Value US$233,076
1.5
Clarus IV-A, L.P. Large shareholder
Transaction date
Purchase
Price
12.00
Quantity 97,131 +17.5%
Value US$1,165,572
1.5
Clarus IV-A, L.P. Large shareholder
Transaction date
Purchase
Price
12.00
Quantity 52,660 +17.5%
Value US$631,920
1.5
Clarus IV-A, L.P. Large shareholder
Transaction date
Purchase
Price
12.00
Quantity 80,786 +17.5%
Value US$969,432
2.3
Novo Holdings A/S SEE REMARKS Large shareholder
Transaction date
Purchase
Price
12.00
Quantity 500,000 +17.2%
Value US$6,000,000
Sofinnova Venture Partners IX, L.P. Large shareholder
Transaction date
Purchase
Price
12.00
Quantity 750,000 +32.1%
Value US$9,000,000
New Enterprise Associates 14, L.P. Large shareholder
Transaction date
Purchase
Price
12.00
Quantity 416,666 +10.6%
Value US$4,999,992
Novartis Bioventures Ltd Large shareholder
Transaction date
Purchase
Price
12.00
Quantity 250,000 +7.6%
Value US$3,000,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-11-24 2025-11-20 S Sale
2.6
Sorensen Mel

President and CEO

Executive Director
3,343 +1.0%
235.78
US$464,447 		3,343 +1.0% 235.78 US$464,447
2025-11-20 2025-11-20 PrS Proposed sale
2.6
Sorensen Mel

Officer

Officer
816
289.73
US$4,580,759 		816 289.73 US$4,580,759
2025-01-02 2024-12-30 B Purchase
CHANG NANCY T
Non-Executive Director Large shareholder
63,773 +36.8%
358.69
US$4,740,093 		63,773 +36.8% 358.69 US$4,740,093
2024-08-20 2024-08-16 S Sale
2.6
Sorensen Mel

President and CEO

Executive Director
67,015 -20.2%
0.07
US$4,825 		67,015 -20.2% 0.07 US$4,825
2024-08-16 2024-08-16 PrS Proposed sale
2.6
Sorensen Mel

Officer; Director

Executive Director
67,015
0.07
US$4,825 		67,015 0.07 US$4,825
2024-02-26 2024-02-08 B Purchase
2.7
Schneid Yair
Large shareholder
150,000 +1.9%
0.17
US$25,650 		150,000 +1.9% 0.17 US$25,650
2024-02-26 2024-02-07 B Purchase
2.7
Schneid Yair
Large shareholder
150,000 +1.9%
0.17
US$25,935 		150,000 +1.9% 0.17 US$25,935
2024-02-26 2024-02-07 B Purchase
2.7
Schneid Yair
Large shareholder
25,000 +0.3%
0.17
US$4,250 		25,000 +0.3% 0.17 US$4,250
2024-02-26 2024-02-06 B Purchase
2.7
Schneid Yair
Large shareholder
25,000 +0.3%
0.20
US$5,025 		25,000 +0.3% 0.20 US$5,025
2024-02-26 2024-02-05 B Purchase
2.7
Schneid Yair
Large shareholder
97,402 +1.3%
0.18
US$17,922 		97,402 +1.3% 0.18 US$17,922
2024-02-26 2024-01-30 B Purchase
2.7
Schneid Yair
Large shareholder
335,000 +4.6%
0.18
US$60,635 		335,000 +4.6% 0.18 US$60,635
2024-02-26 2024-01-29 B Purchase
2.7
Schneid Yair
Large shareholder
150,000 +2.1%
0.18
US$27,000 		150,000 +2.1% 0.18 US$27,000
2023-03-20 2023-03-16 B Purchase
3.2
Bachleda Mark

Chief Commercial Officer

Officer
11,000 +inf%
2.25
US$24,717 		11,000 +inf% 2.25 US$24,717
2023-03-14 2023-03-13 B Purchase
2.2
Degnan Chris

Chief Financial Officer

Officer
10,000 +inf%
1.96
US$19,593 		10,000 +inf% 1.96 US$19,593
2023-03-14 2023-03-10 B Purchase
2.6
Sorensen Mel

President and CEO

Executive Director
100,000 +43.1%
1.68
US$168,120 		100,000 +43.1% 1.68 US$168,120
2021-12-20 2021-12-17 B Purchase
2.7
West Linda
Non-Executive Director
20,000 +50.0%
2.74
US$54,804 		20,000 +50.0% 2.74 US$54,804
2021-09-03 2021-09-01 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
47,756 -100.0%
8.47
US$404,498 		47,756 -100.0% 8.47 US$404,498
2021-06-17 2021-06-15 B Purchase
2.7
West Linda
Non-Executive Director
10,000 +33.3%
9.13
US$91,300 		10,000 +33.3% 9.13 US$91,300
2021-06-04 2021-06-02 B Purchase
2.7
West Linda
Non-Executive Director
10,000 +50.0%
8.65
US$86,511 		10,000 +50.0% 8.65 US$86,511
2021-06-03 2021-06-01 B Purchase
1.8
Alleva Lawrence M
Non-Executive Director
4,045 +inf%
8.59
US$34,741 		4,045 +inf% 8.59 US$34,741
2021-06-02 2021-06-01 B Purchase
2.7
West Linda
Non-Executive Director
10,000 +100.0%
8.64
US$86,381 		10,000 +100.0% 8.64 US$86,381
2021-06-02 2021-05-28 B Purchase
2.7
West Linda
Non-Executive Director
10,000 +inf%
8.64
US$86,410 		10,000 +inf% 8.64 US$86,410
2021-02-19 2021-02-18 S Sale
2.3
Novo Holdings A/S
Large shareholder
500,000 -16.9%
10.58
US$5,290,000 		500,000 -16.9% 10.58 US$5,290,000
2020-11-17 2020-11-13 B Purchase
1.8
Alleva Lawrence M
Non-Executive Director
2,325 +58.1%
10.22
US$23,771 		2,325 +58.1% 10.22 US$23,771
2020-11-16 2020-11-13 S Sale
1.1
Sussman Joel F.

Chief Accounting Officer

Officer
10,000 -100.0%
10.32
US$103,197 		10,000 -100.0% 10.32 US$103,197
2020-11-16 2020-11-12 S Sale
1.1
Sussman Joel F.

Chief Accounting Officer

Officer
10,000 -100.0%
10.06
US$100,627 		10,000 -100.0% 10.06 US$100,627
2020-10-28 2020-10-26 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
2,244 -100.0%
15.00
US$33,660 		2,244 -100.0% 15.00 US$33,660
2020-10-19 2020-10-15 S Sale
2.3
Novo Holdings A/S
Large shareholder
450,000 -13.2%
11.00
US$4,950,000 		450,000 -13.2% 11.00 US$4,950,000
2020-10-07 2020-10-06 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
10,536 -100.0%
12.00
US$126,432 		10,536 -100.0% 12.00 US$126,432
2020-10-07 2020-10-05 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
100 -100.0%
12.00
US$1,200 		100 -100.0% 12.00 US$1,200
2020-06-22 2020-06-19 S Sale
2.7
Novartis Bioventures Ltd

Former 10% Owner
1,001,312 -28.9%
8.25
US$8,260,824 		1,001,312 -28.9% 8.25 US$8,260,824
2020-06-22 2020-06-18 S Sale
2.7
Novartis Bioventures Ltd

Former 10% Owner
900 -0.0%
9.04
US$8,136 		900 -0.0% 9.04 US$8,136
2020-06-17 2020-06-17 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
4,622 -0.1%
9.27
US$42,846 		4,622 -0.1% 9.27 US$42,846
2020-06-17 2020-06-16 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
8,600 -0.2%
9.30
US$79,980 		8,600 -0.2% 9.30 US$79,980
2020-06-17 2020-06-15 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
6,164 -0.2%
9.05
US$55,784 		6,164 -0.2% 9.05 US$55,784
2020-06-12 2020-06-12 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
1,500 -0.0%
9.19
US$13,785 		1,500 -0.0% 9.19 US$13,785
2020-06-12 2020-06-11 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
7,200 -0.2%
9.21
US$66,312 		7,200 -0.2% 9.21 US$66,312
2020-06-12 2020-06-10 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
8,532 -0.2%
9.46
US$80,713 		8,532 -0.2% 9.46 US$80,713
2020-06-09 2020-06-09 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
7,000 -0.2%
9.38
US$65,660 		7,000 -0.2% 9.38 US$65,660
2020-06-09 2020-06-08 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
5,659 -0.2%
9.66
US$54,666 		5,659 -0.2% 9.66 US$54,666
2020-06-09 2020-06-05 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
8,652 -0.2%
9.66
US$83,578 		8,652 -0.2% 9.66 US$83,578
2020-06-04 2020-06-04 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
4,088 -0.1%
9.55
US$39,040 		4,088 -0.1% 9.55 US$39,040
2020-06-04 2020-06-03 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
5,208 -0.1%
9.78
US$50,934 		5,208 -0.1% 9.78 US$50,934
2020-06-04 2020-06-02 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
5,669 -0.2%
9.68
US$54,876 		5,669 -0.2% 9.68 US$54,876
2020-05-28 2020-05-26 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
692 -100.0%
12.00
US$8,304 		692 -100.0% 12.00 US$8,304
2020-05-22 2020-05-21 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
1,174 -100.0%
12.00
US$14,088 		1,174 -100.0% 12.00 US$14,088
2020-05-22 2020-05-20 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
969 -100.0%
12.00
US$11,628 		969 -100.0% 12.00 US$11,628
2020-05-12 2020-05-12 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
671 -100.0%
12.00
US$8,052 		671 -100.0% 12.00 US$8,052
2020-05-12 2020-05-11 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
185 -100.0%
12.00
US$2,220 		185 -100.0% 12.00 US$2,220
2020-05-12 2020-05-08 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
5,102 -100.0%
12.00
US$61,224 		5,102 -100.0% 12.00 US$61,224
2020-05-07 2020-05-07 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
2,059 -100.0%
12.00
US$24,709 		2,059 -100.0% 12.00 US$24,709
2020-05-07 2020-05-06 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
1,489 -100.0%
12.00
US$17,868 		1,489 -100.0% 12.00 US$17,868
2020-05-07 2020-05-05 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
3,064 -100.0%
12.16
US$37,258 		3,064 -100.0% 12.16 US$37,258
2019-12-17 2019-12-13 B Purchase Alleva Lawrence M Non-Executive Director
4,000 +inf%
9.78
US$39,139 		4,000 +inf% 9.78 US$39,139
2019-11-14 2019-11-12 B Purchase
1.5
Clarus IV-A, L.P.
Large shareholder
19,423 +17.5%
12.00
US$233,076 		19,423 +17.5% 12.00 US$233,076
2019-11-14 2019-11-12 B Purchase
1.5
Clarus IV-A, L.P.
Large shareholder
97,131 +17.5%
12.00
US$1,165,572 		97,131 +17.5% 12.00 US$1,165,572
2019-11-14 2019-11-12 B Purchase
1.5
Clarus IV-A, L.P.
Large shareholder
52,660 +17.5%
12.00
US$631,920 		52,660 +17.5% 12.00 US$631,920
2019-11-14 2019-11-12 B Purchase
1.5
Clarus IV-A, L.P.
Large shareholder
80,786 +17.5%
12.00
US$969,432 		80,786 +17.5% 12.00 US$969,432
2019-11-14 2019-11-12 B Purchase
2.3
Novo Holdings A/S

SEE REMARKS

Large shareholder
500,000 +17.2%
12.00
US$6,000,000 		500,000 +17.2% 12.00 US$6,000,000
2019-11-14 2019-11-12 B Purchase
1.5
Blackstone Clarus GP L.P.
Large shareholder
19,423 +17.5%
12.00
US$233,076 		19,423 +17.5% 12.00 US$233,076
2019-11-14 2019-11-12 B Purchase
1.5
Blackstone Clarus GP L.P.
Large shareholder
97,131 +17.5%
12.00
US$1,165,572 		97,131 +17.5% 12.00 US$1,165,572
2019-11-14 2019-11-12 B Purchase
1.5
Blackstone Clarus GP L.P.
Large shareholder
52,660 +17.5%
12.00
US$631,920 		52,660 +17.5% 12.00 US$631,920
2019-11-14 2019-11-12 B Purchase
1.5
Blackstone Clarus GP L.P.
Large shareholder
80,786 +17.5%
12.00
US$969,432 		80,786 +17.5% 12.00 US$969,432
2019-11-12 2019-11-12 B Purchase Sofinnova Venture Partners IX, L.P. Large shareholder
750,000 +32.1%
12.00
US$9,000,000 		750,000 +32.1% 12.00 US$9,000,000
2019-11-12 2019-11-12 B Purchase New Enterprise Associates 14, L.P. Large shareholder
416,666 +10.6%
12.00
US$4,999,992 		416,666 +10.6% 12.00 US$4,999,992
2019-11-12 2019-11-12 B Purchase Novartis Bioventures Ltd Large shareholder
250,000 +7.6%
12.00
US$3,000,000 		250,000 +7.6% 12.00 US$3,000,000
Explore more

More insider trading research around Galera Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America